This site is intended for healthcare professionals only
LoginRegister
SEC Approves Serums Salk Polio Vaccine for Commercial Use, Recommends Phase I Trial for 21-valent Pneumococcal VaccineRevise Phase I/II CT protocol: CDSCO panel tells Serum Institute of India on Dengue Tetravalent...
Moderna, Merck cancer vaccine plus Keytruda delays skin cancer returnModerna, Merck cancer vaccine plus Keytruda delays skin cancer return
Surge in COVID-19 cases: Booster shot to prevent infection may do more harm than good, says AIIMS doctorSurge in COVID-19 cases: Booster shot to prevent infection may do more harm than good, says AIIMS...
USFDA nod to Zydus Eluxadoline tablets for irritable bowel syndrome with diarrhoeaRevise Phase IV CT Protocol: CDSCO panel tells Zydus Lifesciences on Typhoid Vi Conjugate Vaccine...
ICMR Seeks Partners for Malaria Vaccine CommercialisationUniversity of Oxford Malaria vaccine gets regulatory clearance for use in Ghana
Robust and variable immunity during COVID-19 in pregnant women observed in studyRobust and variable immunity during COVID-19 in pregnant women observed in study
Flu vaccine did not meet criteria for early success in late-stage trial: ModernaFlu vaccine did not meet criteria for early success in late-stage trial: Moderna
Serum Institute Covovax likely to be available at Rs 225 per dose on CoWIN portalSerum Institute Covovax likely to be available at Rs 225 per dose on CoWIN portal
Merck gets USFDA Priority Review for application for Keytruda plus standard of care as Perioperative treatment for Resectable Locally Advanced Head, Neck Squamous Cell CarcinomaMerck, Moderna get PRIME scheme designation from EMA for personalized mRNA cancer vaccine, KEYTRUDA...
Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic DermatitisPfizer RSV vaccine 82 percent effective in severe infection in infants: Data
COVID vaccine: SII seeks inclusion of Covovax on CoWIN as heterologous booster dose for adultsCOVID vaccine: SII seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults
Low-risk groups no longer require COVID-19 boosters, recommends WHOLow-risk groups no longer require COVID-19 boosters, recommends WHO
X